Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression

2021 ◽  
Author(s):  
Nobuaki Ochi ◽  
Eiki Ichihara ◽  
Nagio Takigawa ◽  
Daijiro Harada ◽  
Koji Inoue ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

2020 ◽  
Vol 21 (5) ◽  
pp. e497-e510 ◽  
Author(s):  
Elisa Gobbini ◽  
Anne Claire Toffart ◽  
Maurice Pérol ◽  
Jean-Baptiste Assié ◽  
Michaël Duruisseaux ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Precision Management of Advanced Non–Small Cell Lung Cancer

2020 ◽  
Vol 71 (1) ◽  
pp. 117-136 ◽  
Author(s):  
Ching-Yao Yang ◽  
James Chih-Hsin Yang ◽  
Pan-Chyr Yang
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non–small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non–small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future.

Sign in / Sign up

Export Citation Format

Share Document